TSY-120 - Enhertu (T-DXd) Biosimilar

 

Category: Pharmaceutical

Exhibitor: FORMOSA PHARMACEUTICALS , INC

Booth No: M318

 

Characteristic

 

√ Enhertu® ADC Biosimilar: TSY-120 is a biosimilar program developed for the groundbreaking Antibody-Drug Conjugate (ADC) Enhertu®
√ HER2 Treatment: It provides an equally effective and high-quality treatment option for patients battling HER2-positive and HER2-low breast cancers.
√ Additionally, Enhertu® has successfully received approvals for over 10 indications globally, targeting several other HER2-related challenging malignancies beyond breast cancer.
√ Global "First-Mover" Advantage: The strategic objective is to become the first Enhertu® biosimilar to successfully launch on the global market.
√ By leveraging the development experience from the earlier TSY-110 project, it cultivates a distinct first-mover advantage.
√ High Economic Efficiency: It offers a more economical treatment option and aims to serve as a crucial alternative for health insurance providers globally, alleviating the economic burden of medical care while expanding patient access.
√ R&D and Manufacturing in Taiwan: Co-developed by Formosa Pharmaceuticals and EirGenix, and capitalizing on the manufacturing capabilities of Formosa Laboratories, this collaboration creates a comprehensive "one-stop" solution for research, development, and manufacturing entirely within Taiwan, ensuring a highly stable supply chain.
√ Targeting a Multi-Billion Dollar Market: It addresses the immense demand driven by the rising incidence of HER2-positive breast cancer, as well as the new "HER2-low" classification which accounts for approximately 55% of patients previously categorized as HER2-negative.
√Global sales of Enhertu® are projected to exceed a staggering $13 billion USD by 2032, representing immense market potential.

 

Other Products

 

• 

  TSY-110 - Kadcyla (T-DM1) Biosimilar

• 

  APNT Nanoparticle Formulation Platform

• 

  APP13007 - Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery

• 

  TSY-310 - A Next-Generation Novel Bispecific ADC

• 

  APP13002 - Infectious Eye Diseases Treatment

 

 

 

Back